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Abstract
Background: Inflammation caused by the Lyme disease spirochete B. burgdorferi is an important factor in the
pathogenesis of Lyme neuroborreliosis. Our central hypothesis is that B. burgdorferi can cause disease via the induction of
inflammatory mediators such as cytokines and chemokines in glial and neuronal cells. Earlier we demonstrated that
interaction of B. burgdorferi with brain parenchyma induces inflammatory mediators in glial cells as well as glial
(oligodendrocyte) and neuronal apoptosis using ex vivo and in vivo models of experimentation.
Methods: In this study we evaluated the ability of live B. burgdorferi to elicit inflammation in vitro in differentiated human
MO3.13 oligodendrocytes and in differentiated primary human oligodendrocytes, by measuring the concentration of
immune mediators in culture supernatants using Multiplex ELISA assays. Concomitant apoptosis was quantified in these
cultures by the in situ terminal deoxynucleotidyl transferase mediated UTP nick end labeling (TUNEL) assay and by
quantifying active caspase-3 by flow cytometry. The above phenomena were also evaluated after 48 h of stimulation with
B. burgdorferi in the presence and absence of various concentrations of the anti-inflammatory drug dexamethasone.
Results: B. burgdorferi induced enhanced levels of the cytokine IL-6 and the chemokines IL-8 and CCL2 in MO3.13 cells as
compared to basal levels, and IL-8 and CCL2 in primary human oligodendrocytes, in a dose-dependent manner. These
cultures also showed significantly elevated levels of apoptosis when compared with medium controls. Dexamethasone
reduced both the levels of immune mediators and apoptosis, also in a manner that was dose dependent.
Conclusions: This finding supports our hypothesis that the inflammatory response elicited by the Lyme disease
spirochete in glial cells contributes to neural cell damage. As oligodendrocytes are vital for the functioning and survival of
neurons, the inflammation and subsequent apoptosis of oligodendrocytes induced by B. burgdorferi could contribute to
the pathogenesis of Lyme neuroborreliosis.
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Background
Lyme neuroborreliosis (LNB) in the US is manifest in 10%
to 15% of patients diagnosed with Lyme disease [1,2]. In
addition to the classical neurological triad of meningitis,
cranial neuritis, and radiculitis, LNB may also manifest, al-
beit more rarely, as encephalopathy, encephalomyelitis
[3,4], and cerebellitis [5]. Acute transverse myelitis, caused
by inflammatory processes of the spinal cord resulting in
axonal demyelination, has also been reported in LNB
patients [6-9]. In the peripheral nervous system (PNS),
Lyme disease appears as neuritis with patchy multifocal
axonal degeneration associated with epineural perivascular
inflammation [10,11].
LNB patients may experience a wide array of neuro-
logical and neuropsychiatric symptoms as a result of white
matter inflammation that results in a subacute multiple
sclerosis (MS)-like manifestation [12,13]. Brain magnetic
resonance imaging (MRI) of LNB patients that was suggest-
ive of a demyelinating disease, with MS-like symptoms that
responded well to antibiotic therapy, has been reported
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[14,15]. It has been hypothesized that B. burgdorferi may
exacerbate MS or be a trigger for an MS-like inflammatory
demyelinating disease of the central nervous system (CNS)
by activating myelin-specific T cells via molecular mimicry
[16,17], or by bystander activation via inflammatory cyto-
kines [16].
Encephalitis associated with LNB involves white mat-
ter more often than gray matter [4,18,19]. Inflammatory
lesions in the brain and spinal cord show multifocal en-
cephalitis with large areas of demyelination in perivascu-
lar white matter commonly associated with the presence
of B. burgdorferi DNA [6,20-22]. Astroglial and neuronal
proteins, anti-myelin antibodies and cells secreting anti-
bodies to myelin basic protein have been detected in the
cerebrospinal fluid (CSF) of patients with LNB, indicating
possible glial and neuronal damage in the CNS parenchyma
[23-25]. There is evidence that B. burgdorferi spirochetes
can adhere to neurons, CNS glia, and Schwann cells from
studies in neuronal and glial cell lines and primary rat brain
cultures [26], and that B. burgdorferi can adhere to and per-
haps invade human neuroglial and cortical neuronal cells
[27]. Adhesion was found to be associated with galactocer-
ebroside, a glycolipid component of myelin, and oligoden-
drocytes in primary brain cultures were shown to be
damaged, by scanning electron microscopy [26,28,29]. Cells
that secrete antibodies to myelin basic protein have been
found in CSF of patients with LNB, suggesting damage to
oligodendrocytes possibly as a result of demyelination [24].
Cytokines and chemokines are key immune mediators
that play an important role in promoting CNS injury in
various kinds of inflammatory neurodegenerative
diseases [30-34]. Various inflammatory cytokines and
chemokines have been reported in the CSF of patients
with LNB [35-38].
We hypothesize that B. burgdorferi can cause disease via
the induction of inflammatory mediators such as cytokines
and chemokines in glial and neuronal cells. Earlier we
demonstrated that interaction of B. burgdorferi with brain
parenchyma induces inflammatory mediators in glial cells
as well as glial (oligodendrocyte) and neuronal apoptosis
[39]. Further, we found that a similar inflammatory re-
sponse occurs in vivo, as demonstrated in rhesus monkeys
inoculated intrathecally with live B. burgdorferi. This
resulted in elevation of IL-6, IL-8, CCL2, and CXCL13 in
the CSF within 1 week post infection, accompanied with
histopathological changes consistent with acute neuro-
logical Lyme disease such as leptomeningitis and radiculi-
tis, as well as satellite glial cell and neuronal apoptosis in
the dorsal root ganglia [40].
Here we assessed the ability of live B. burgdorferi to elicit
inflammatory mediators in cultures of differentiated human
MO3.13 oligodendrocytes [41], and primary cultures of dif-
ferentiated human oligodendrocyte precursor cells (HOPC).
Further, we examined the ability of live B. burgdorferi to
induce apoptosis of oligodendrocytes, and quantified apop-
tosis in the above cultures by the in situ TUNEL assay, and
by measuring activated caspase-3 by flow cytometry. The
role of inflammation in mediating apoptosis of oligodendro-
cytes, as induced by B. burgdorferi was studied by evaluat-
ing the above phenomena after 48 h of stimulation with B.
burgdorferi in the presence and absence of various concen-
trations of the anti-inflammatory drug dexamethasone, a
glucocorticoid used in the treatment of immune-mediated
inflammatory diseases [42].
Methods
Maintenance and differentiation of MO3.13 cultures
The human oligodendrocyte cell line MO3.13 was obtained
from CELLutions Biosystems Inc. (Burlington, Ontario,
Canada). Cells were revived as per the manufacturer’s
instructions and maintained in complete growth medium
(CGM) consisting of Dulbecco’s minimal essential medium
(DMEM) (high glucose) (Invitrogen, Carlsbad, CA), 10%
fetal bovine serum (ThermoFisher, Waltham, MA, USA),
and antibiotics, 100 units of penicillin and 100 μg of
streptomycin (P/S) (Invitrogen), in a humidified incubator
with an atmosphere of 5% CO2, set at 37°C. Cells were
maintained in CGM for 3 days, after which the medium
was replaced by differentiation medium (DM), consisting of
DMEM, P/S, and phorbol 12-myristate 13-acetate (Sigma,
St. Louis, MO, USA), at a concentration of 100 nM, and de-
void of serum. Cells were cultured in DM for 4 days, after
which time they were used in experiments.
MO3.13 cells were also seeded in Lab-Tek II CC2
chamber slides containing two wells (Nunc, Rochester,
NY, USA) at a density of 0.5 x 104 cells per well, and
maintained in 2 mL CGM followed by DM as described
above for the purpose of evaluating phenotypic markers
using immunofluorescence staining and confocal mi-
croscopy, as well as for evaluation of apoptosis by the in
situ TUNEL assay. Typically, the final cell count in
chamber slides after maintenance in CGM for 3 days fol-
lowed by DM for 4 days was 2.5 x 104 cells per well.
Cells were seeded into six-well plates at a seeding dens-
ity of 2 x 104 cells per well for evaluation of inflamma-
tory mediators and for flow cytometry experiments.
Typically, the final cell density after differentiation in
six-well plates was 2.5 x 105 cells per well. Only differen-
tiated MO3.13 cells were used for estimation of inflam-
matory mediators or for the evaluation of apoptosis,
described below.
Human oligodendrocyte precursor cells (HOPC)
HOPC were cultured on poly-L-Lysine coated chamber
slides containing two wells at a seeding density of 8 x 104
cells per well, as recommended by the provider (ScienCell
Inc., Carlsbad, CA, USA). Cells were revived by thawing cul-
tures as per the manufacturer’s instructions and maintained
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in ‘precursor medium’ for 8 days, after which they were
maintained in ‘differentiation medium’ for 3 days prior to
commencing experiments. Both media were supplied by the
manufacturer, and their composition is proprietary. The final
cell count after differentiation was comparable to the initial
seeding density. The HOPC differentiated into mature cells
with longer cell processes, as indicated by the manufacturer.
Differentiated HOPC maintained on poly-L-Lysine-coated
chamber slides were used for the evaluation of both secreted
immune mediators as well as apoptosis by the in situ
TUNEL assay.
Stimulation of differentiated MO3.13 oligodendrocytes
and HOPC cultures with live B. burgdorferi for evaluation
of immune mediators and apoptosis
B. burgdorferi strain B31 5A19 passage 3 was grown in
Barbour-Stoenner-Kelly-H (BSK-H) medium, supplemented
with 6% rabbit serum (Sigma, St. Louis, MO, USA) and
antibiotics (rifampicin at 45.4 mg/mL, phosphomycin at
193 mg/mL and amphotericin at 0.25 mg/mL) to late loga-
rithmic phase under microaerophilic conditions. Spiro-
chetes were pelleted at 2000 x g for 30 min at RT. At the
end of the run the rotor was left to coast without breaking
so as to minimize damage to the live spirochetes. The dif-
ferentiated MO3.13 cultures were washed in DM devoid of
P/S. The B. burgdorferi culture was washed twice using
phosphate buffered saline (PBS) pH 7.2 (Invitrogen, Grand
Island, NY, USA) and resuspended in DM at a concentra-
tion so as to achieve the desired multiplicity of infection
(MOI). Controls with no spirochetes were also included.
Cultures were incubated for 48 h in a humidified 5% CO2
incubator, set at 37°C. At the 48-h time point culture super-
natants were collected for evaluation of inflammatory med-
iators. Culture supernatants were centrifuged at 4°C at
2000 x g for 30 min to remove any suspended bacteria and
the supernatant was aliquoted and stored at -80°C until
used. The oligodendrocyte cultures were then fixed in 2%
paraformaldehyde as described below for assessment of
apoptosis. Spirochetes remained motile after 48-h incuba-
tion in MO3.13 or HOPC differentiation medium. Assess-
ment of motility after incubation in MO3.13 differentiation
medium required re-culturing spirochetes in BSK-H.
Immunofluorescence staining and confocal microscopy
MO3.13 cells were either held in CGM for 3 days or fur-
ther incubated in DM for 4 days for evaluation of
phenotypic markers pre- and post-differentiation, re-
spectively. Only differentiated HOPC cultures were used
for evaluation of phenotypic markers.
Medium was removed and cells were fixed in 2%
paraformaldehyde in PBS (PFA) (USB, Cleveland, OH,
USA) at RT for 10 min with gentle rocking on a rocker in
the dark. PFA was removed with three washes using PBS,
each for 5 min at RT on the rocker. Cells were then given
a post-fixation permeabilization treatment using a mixture
of ethanol:acetic acid (2:1) (Sigma) for 5 min at -20°C.
Cells were washed thrice with PBS as described above.
The slides were then detached from the chamber by pla-
cing the chambers in 70% methanol for 10 min and fol-
lowing the manufacturer’s instructions (Nunc). Detached
slides were transferred to slide holders containing PBS-
FSG-TX-100 buffer (phosphate-buffered saline pH 7.4
containing 0.2% fish skin gelatin (Sigma), and 0.02% Tri-
ton X-100 (MP Biomedicals, Solon, OH, USA), and 0.02%
sodium azide (Sigma), and held in this buffer for 15 min
with gentle rocking at RT for permeabilization, followed
by a rinse with PBS-FSG (phosphate-buffered saline con-
taining 0.2% fish skin gelatin and 0.02% sodium azide).
Slides were then blocked in a buffer consisting of PBS
containing 10% normal goat serum (Invitrogen) and 0.02%
sodium azide (NGS) for 1 h in a humidified chamber at RT,
followed by incubation with respective primary antibodies;
rabbit polyclonal anti-human myelin basic protein (MBP)
Clone AB 980 at 1:100 (Millipore, Billerica, MA, USA), or
mouse monoclonal IgG1 anti-human glial fibrillary acidic
protein (GFAP), Clone G-A-5 at 1:200 (Sigma). Relevant
isotype controls (Sigma) at the same concentrations as their
respective primary antibodies were also included.
All primary antibodies at the appropriate concentrations
were left on the slides for 1 h at RT, in a humidifying box.
The slides were then rinsed with PBS-FSG-TX-100 buffer
and then held in this buffer for 5 min, followed by a rinse
with PBS-FSG buffer. The relevant secondary antibodies,
either goat anti-mouse or goat anti-rabbit (Invitrogen) at a
dilution of 1:1000 in NGS, were applied to the slides and
left in the humidified dark slide-box at RT for 30 to 45 min.
Secondary antibodies were conjugated to one of the Alexa
fluorochromes- Alexa 488 (green) or 568 (red). Slides were
washed and rinsed as described above and then incubated
with a nuclear stain TOPRO-3 (Invitrogen) at 1:1000 in
NGS for 15 min. After a final wash in PBS-FSG-TX-100
buffer followed by a rinse in PBS-FSG, slides were mounted
in anti-quenching medium (Sigma). The stained and
mounted slides were stored in the dark at 4°C until they
were viewed under a confocal microscope. MO3.13 cultures
were evaluated for the expression of MBP as well as GFAP,
while HOPC cells were only stained for the evaluation of
MBP expression. Slides with MO3.13 and HOPC oligoden-
drocytes were also stained with isotype controls for the pri-
mary antibodies at protein concentrations used for the
respective primary antibodies.
Confocal microscopy was performed using a Leica
TCS SP2 confocal microscope equipped with three
lasers (Leica Microsystems, Exton, PA, USA). Images of
individual channels were merged to obtain images con-
taining all channels. Photoshop CS3 (Adobe systems
Inc., San Jose, CA, USA) was used to assign colors to
each fluorochrome.
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Evaluation of immune mediators from culture
supernatants
The concentrations of cytokines and chemokines present
in the culture supernatants were quantified using the
Human 14-plex Cytokine-Chemokine Array kit (Milli-
pore), following the manufacturer’s instructions. The
analytes detected by this panel are: Hu IL-1β, Hu IL-2,
Hu IL-4, Hu IL-5, Hu IL-6, Hu IL-7, Hu IL-8, Hu IL-10,
Hu IL-12 (p70), Hu IL-13, Hu GMCSF, Hu IFN-γ, Hu
CCL2, and Hu TNF-α. The multiplex plate was read
using a Bio-Plex 200 Suspension Array Luminex System
(Bio-Rad, Hercules, CA, USA).
Evaluation of apoptosis by in situ TUNEL assay
Cells contained in chamber slides were labeled for MBP
by immunofluorescence staining as described above. Slides
were then fixed with 2% PFA, washed three times with
PBS by rinsing slides in PBS and holding them in PBS for
2 min between washes. Slides were then subjected to the
TUNEL ApopTagPlus fluorescein in situ apoptosis assay
(Chemicon, Temecula, CA, USA) as per the manufac-
turer’s instructions. Slides were then mounted as described
above and stored at 4°C in the dark until viewed. The per-
centage of apoptotic oligodendrocytes from 10 fields was
evaluated from each chamber area by counting the total
number of MBP-positive cells (at least 500 cells) from
each of the chamber areas, followed by the number of cells
that showed co-localization of both the TUNEL signal and
MBP expression. All counts were made by viewing slides
under a fixed magnification of 63× (corresponding to an
area of 0.05 mm2) using the confocal microscope.
Evaluation of the role of inflammation in mediating
oligodendrocyte apoptosis using the anti-inflammatory
drug dexamethasone
MO3.13 cell cultures were seeded as described above in
chamber slides for evaluation of apoptosis or in six-well
plates for evaluation of immune mediators, and main-
tained in growth and differentiation medium as described.
Prior to stimulation with live B. burgdorferi, differentiated
cultures were incubated with various concentrations of
dexamethasone (water soluble), 5 μM, 15 μM, and 150
μM (Sigma) for 24 h at 37°C, after which they were
washed and then incubated in fresh differentiation
medium containing the respective concentrations of dexa-
methasone and live B. burgdorferi at a MOI of 10:1 at 37°
C for 48 h and devoid of P/S. Similar concentrations of
dexamethasone as those mentioned above have been
reported to inhibit the production of CCL2 in mice micro-
glia [43]. Dexamethasone is supplied as a water-soluble
formulation consisting of dexamethasone and a carrier
substance (2-hydroxypropyl)-β-cyclodextrin. The effect of
the carrier alone, at the respective molar concentrations
accompanying dexamethasone was assessed by incubating
MO3.13 oligodendrocytes as described above in the pres-
ence and absence of B. burgdorferi and carrier alone at 15,
45, and 450 μM, respectively.
After 48 h, culture supernatants were collected and
processed for evaluation of inflammatory mediators, and
cells were fixed and evaluated for apoptosis by the in
situ TUNEL assay as described above. Medium controls
that were pretreated and then incubated with the same
respective concentrations of dexamethasone but without
the addition of live B. burgdorferi were also included.
The effect of dexamethasone on differentiated HOPC
was also evaluated as described above.
Evaluation of expression of MBP and active caspase-3 by
immunofluorescence staining and flow cytometry
Differentiated MO3.13 cell cultures that were main-
tained in six-well plates and were stimulated with B.
burgdorferi at a MOI of 10:1 for 48 h in DM devoid of
P/S were used in this experiment. Most of the medium
covering the cells was removed and centrifuged gently at
300 x g for 10 min to collect any cells that were dis-
lodged due to cell death. This cell pellet was combined
with the cells harvested after trypsinization for 3 min at
37°C. The cells were washed with PBS and pelleted at
1800 rpm for 10 min at RT, and used for staining for
MBP and active caspase-3 as described below.
For flow cytometry staining of MBP, cells harvested
from the various conditions were distributed into ali-
quots of cell suspensions adjusted to a cell count of 1 x
106, each in a total volume of 250 μL of PBS, followed
by fixation and permeabilized using 250 μL of Cytofix/
Cytoperm (BD Biosciences, San Diego, CA, USA) for 20
min at RT in the dark with gentle rocking. Cells were
then washed in 1 mL of Perm/Wash buffer (BD Bios-
ciences) and pelleted at 700 x g for 10 min at RT. Cell
pellets were resuspended in 150 μL of PBS and incu-
bated with 20 μL of primary rabbit anti-MBP antibody
(Millipore) for 60 min at RT. Stained cells were then
washed once with the Perm/Wash buffer as described
above, resuspended in 150 μL of PBS, and stained fur-
ther with 1 μL (2 μg of protein) of secondary antibody,
goat anti-rabbit IgG-Alexa 488 (Invitrogen) for 30 min
at RT in the dark. Cells were then washed with the
Perm/Wash buffer and fixed using 300 μL of 2% PFA.
For detection of oligodendrocyte apoptosis, cells were
previously stained for MBP using primary and secondary
antibody as described, and washed and pelleted using
the Perm/Wash buffer. Cell pellets were then resus-
pended in 150 μL of PBS and incubated for 1 h at RT
with 20 μL of phycoerythrin (PE)-conjugated anti-active
caspase-3 antibody (BD), in the dark, for active caspase-
3 staining. Respective controls were included for cells
without antibodies, single-stain controls for primary
MBP antibody, secondary antibody anti-rabbit Alexa
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488, and PE-active-caspase-3 only, for compensation set-
tings. Cells were then washed and pelleted as described
above, and finally fixed using 300 μL of 2% PFA and kept
protected from light at 4°C until analyzed. As no non-
specific binding with isotype control for MBP was previ-
ously found in the immunofluorescence staining method
described above, no isotype control was included here
for flow cytometry evaluation.
Flow cytometric acquisition was performed within 24 h
of staining. At least 100,000 events were collected from
each sample using a FACS Calibur instrument (BD Bios-
ciences). Data were analyzed using FlowJo software
(TreeStar, Inc.) version 9.0.1.
Statistical evaluation
The unpaired-two tailed t test was used to evaluate the
statistical significance between means of datasets, using
Graphpad Prizm software (Graph Pad Software Inc.)
version 4.
Results
Expression of the mature oligodendrocyte marker MBP
by differentiated MO3.13 cells and differentiated HOPC
MO3.13 cell cultures held in growth medium expressed
both MBP and GFAP (Figure 1A). Upon differentiation,
mature MO3.13 oligodendrocytes showed elongated cell
processes and continued to express MBP, while showing
reduced GFAP expression as compared to undifferentiated
cells (Figure 1B). Differentiated HOPC also expressed MBP
(not shown in Figure 1, but see Figure 5 B-D). Oligoden-
drocytes incubated with respective isotype controls and
corresponding secondary antibodies did not show any de-
tectable signal (not shown).
Pro-inflammatory response induced by B. burgdorferi in
MO3.13 oligodendrocytes
Live B. burgdorferi spirochetes incubated with differen-
tiated MO3.13 cell cultures for 48 h at a MOI of 10:1
and 100:1 induced significantly elevated levels of CCL2
(Figure 2A), IL-6 (Figure 2B) and IL-8 (Figure 2C) as
compared to the levels induced in medium controls. The
concentration of CCL2 surpassed 8,000 pg/mL and
13,000 pg/mL at MOI of 10:1 and 100:1, respectively,
whereas the constitutive level of this chemokine that
was produced in medium alone was of 5,000 pg/mL
(Figure 2A). The basal concentration of IL-6 was of only
approximately 10 pg/mL but reached more than 130 pg/mL
and 250 pg/mL at MOI of 10:1 and 100:1, respectively
(Figure 2B). IL-8 production displayed a similar pattern but
with higher values than IL-6 (Figure 2C). B. burgdorferi also
induced marginally higher levels of the cytokines GMCSF
and IFN-γ in a dose-dependent manner as compared to
controls (not shown). Data represent mean values and
standard deviations between values of two independent
experiments. The concentration values in each of the two
experiments are the mean of duplicate determinations
within the experiment.
Evaluation of apoptosis of MO3.13 oligodendrocytes in
the presence of B. burgdorferi
Live B. burgdorferi induced apoptosis, as detected by
the in situ TUNEL assay, in differentiated MO3.13
Figure 1 Cell morphology, myelin basic protein, and glial fibrillary acidic protein expression in MO3.13 oligodendrocyte cultures.
MO3.13 cultures maintained in growth medium show expression of myelin basic protein (MBP, in green) and glial fibrillary acidic protein (GFAP
red) (A). TOPRO3, a nuclear stain, appears blue. Upon differentiation, when growth medium is replaced with differentiation medium, cells change
in morphology, continue to show expression of MBP, and the expression of GFAP is decreased (B).
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oligodendrocytes, after 48 h of incubation. Apoptosis
visualized by confocal microscopy in medium alone,
and after incubation with live B. burgdorferi at MOI of
10:1, 100:1, and 500:1 are shown in Figures 3 (A-D), re-
spectively. The mean percent apoptosis and standard
deviations quantified from ten microscope fields (a total
of 500 cells) for each condition is shown in Figure 3E.
Effect of the anti-inflammatory drug dexamethasone on
the pro-inflammatory response elicited by B. burgdorferi
in differentiated MO3.13 oligodendrocytes and
differentiated HOPC
Dexamethasone reduced the levels of CCL2, IL-6, and
IL-8 as induced by live B. burgdorferi (MOI of 10:1)
in MO3.13 oligodendrocytes after 48 h, as shown in
Figures 4A, 4B, and 4C, respectively, in a dose-dependent
fashion. Dexamethasone was able to significantly inhibit the
levels of CCL2, IL-6, and IL-8 as induced by B. burgdorferi
when used at 15 μM and 150 μM (Figure 4A, B, and C).
We confirmed that the anti-inflammatory effect of the dexa-
methasone formulation was due to its dexamethasone frac-
tion and not due to the carrier substance (2-hydroxypropyl)-
β-cyclodextrin (HPC), as HPC alone at 15 μM, 45 μM, and
450 μM, the concentrations at which it is present in the
dexamethasone concentrations used above, failed to reduce
the levels of B. burgdorferi-induced immune mediators
(Figure 4A, B, and C, respectively). Similarly, dexa-
methasone (5 μM, 15 μM, and 150 μM) reduced the
levels of CCL2 and IL-8 as induced by live B. burgdorferi
(MOI of 10:1) in HOPC cells after 48 h of co-incubation
(Figure 4D and E).
Effect of dexamethasone on apoptosis induced by B.
burgdorferi in differentiated MO3.13 oligodendrocytes
and differentiated HOPC
Figure 5A shows percent apoptosis in MO3.13 oligo-
dendrocytes as measured by the in situ TUNEL assay
after 48 h of incubation in medium control (2.85%± 0.91),
with B. burgdorferi alone (16%± 0.89) at MOI of 10:1,
B. burgdorferi+dexamethasone as well as medium+
dexamethasone at 5 μM, 15 μM, and 150 μM. Dexa-
methasone was protective against B. burgdorferi-induced
apoptosis, showing significant reduction in apoptosis at
15 μM (8.93± 0.65) and 150 μM (7.6± 0.99) (P< 0.05).
Figure 2 B. burgdorferi induces CCL2, IL-6 and IL-8 in MO3.13 oligodendrocytes in a dose dependent fashion. Evaluation by the multiplex
ELISA assay of culture supernatants of differentiated MO3.13 oligodendrocytes incubated with live B. burgdorferi spirochetes at a multiplicity of
infection (MOI) of 10:1, and 100:1 for 48 h show elevated levels of CCL2 (A), IL-6 (B), and IL-8 (C) as compared to that observed in medium
controls (* P< 0.05, ** P< 0.01).
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Figure 3 B. burgdorferi induces apoptosis in MO3.13 oligodendrocytes in a dose-dependent manner. Apoptosis detected by the in situ
TUNEL assay (green) in MBP-stained differentiated MO3.13 cells (red), in medium control (A) and after incubation with live B. burgdorferi for 48 h
at multiplicity of infection (MOI) of 10:1 (B), 100:1 (C), and 500:1 (D), as visualized by confocal microscopy. (E) : Graphical representation of the
percent apoptosis as detected by the in situ TUNEL assay in differentiated MO3.13 cells held in medium control and after incubation with live B.
burgdorferi at MOIs of 10:1, 100:1, and 500:1, respectively, for 48 h (*P< 0.05, **P< 0.01, ***P< 0.001).
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However, when dexamethasone was used at the high
concentration of 1,500 μM it appeared to be toxic, as it
not only resulted in higher levels of apoptosis than that
induced by B. burgdorferi alone (84.4%± 1.2), but it also
induced high levels of apoptosis in cells incubated in
medium alone (75.8%) (not shown in Figure 5A).
Live B. burgdorferi also induced enhanced apoptosis as
evaluated by the in situ TUNEL assay and visualized by
Figure 4 Dexamethasone reduces levels of CCL2, IL-6, and IL-8 induced by B. burgdorferi in differentiated oligodendrocytes. Evaluation
by the multiplex ELISA assay of culture supernatants of differentiated MO3.13 oligodendrocytes incubated with live B. burgdorferi spirochetes at a
multiplicity of infection (MOI) of 10:1 for 48 h in the presence and absence of dexamethasone (Dex) at 5 μM, 15 μM, and 150 μM concentrations
and carrier substance (2-hydroxypropyl)-β-cyclodextrin (HPC), at 15 μM, 45 μM, and 450 μM, respectively, showing levels of CCL2 (A), IL-6 (B), and
IL-8 (C). Levels of CCL2 (D) and IL-8 (E) detected in culture supernatants of differentiated primary human oligodendrocytes, as induced by live B.
burgdorferi after 48 h of incubation in the presence and absence of dexamethasone at 5 μM, 15 μM, and 150 μM concentrations (*P< 0.05).
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Figure 5 Dexamethasone protects differentiated human oligodendrocytes from B. burgdorferi-induced apoptosis in a dose dependent
fashion. A graphical representation of the percent apoptosis as evaluated by the in situ TUNEL assay in differentiated MO3.13 oligodendrocytes
(A) in the presence and absence of dexamethasone (Dex) at 5 μM, 15 μM, and 150 μM concentrations. Confocal images showing apoptosis as
observed by the in situ TUNEL assay in differentiated human oligodendrocyte precursor cells (HOPC) incubated for 48 h in medium (B), B.
burgdorferi at MOI of 10:1 (C) and B. burgdorferi (10:1) in the presence of dexamethasone at 5 μM (D). The TUNEL signal is seen in green in
differentiated HOPC showing expression of myelin basic protein (MBP), in red. (E) Graphical representation of the protective effect of
dexamethasone on B. burgdorferi-induced apoptosis in HOPC at 5 μM,15 μM, and 150 μM concentrations, (* P< 0.05).
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confocal microscopy in differentiated HOPC cells,
Figure 5C, as compared to that seen in medium controls,
Figure 5B, after 48 h of incubation. A confocal image of the
protective effect of dexamethasone at 5 μM on B. burgdor-
feri-induced apoptosis is shown in Figure 5D. Figure 5E
shows a graph of the percent apoptosis observed in HOPC
cells when incubated with live B. burgdorferi, and medium
controls in the presence and absence of dexamethasone at 5
μM, 15 μM, and 150 μM after 48 h of incubation. Dexa-
methasone significantly reduced the levels of B. burgdorferi-
induced apoptosis in HOPC cells from (30.19%±4.12) to
12.05%±2.8 in the presence of 5 μM dexamethasone,
14.05%±3.58 at 15 μM, and 13.79%±2 at 150 μM, respect-
ively (P< 0.05).
Caspase-3 activation induced by B. burgdorferi in
differentiated MO3.13 oligodendrocytes
Caspase-3 activation was quantified by flow cytometry in
differentiated MO3.13 cells in the presence and absence
of live B. burgdorferi (Figure 6). Cells were incubated
with spirochetes for 48 h. The percent of MBP-positive
cells showing positive staining for activated caspase-3 in
cultures held in medium (0.18± 0.1) was elevated by 30-
fold in MO3.13 cells incubated with live B. burgdorferi
Figure 6 B. burgdorferi induces elevated levels of activated caspase-3 in differentiated MO3.13 cells. Flow cytometric evaluation of
activated caspase-3 in differentiated MO3.13 cells following incubation in differentiation medium (top panel) and with live B. burgdorferi (MOI,
10:1) for 48 h (bottom panel). The mean percent of MBP-positive cells showing positive staining for activated caspase-3 in cultures held in
medium (0.18± 0.1) was elevated by 30-fold in MO3.13 cells incubated with live B. burgdorferi (5.45± 0.48). The figure shows the results of two
independent experiments.
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(5.45± 0.48). The results represent the mean and stand-
ard deviation of values obtained from two independent
experiments.
Discussion
In recent studies, using ex vivo and in vivo modes of experi-
mentation in the rhesus monkey model of LNB, we had
established that B. burgdorferi is able to induce inflammatory
mediators, with concomitant apoptosis of oligodendrocytes
in the frontal cortex, and of satellite glial cells in dorsal root
ganglia [39,40]. We had also shown with experiments per-
formed in vitro that human neurons co-cultured with B.
burgdorferi and rhesus microglia undergo apoptosis in the
presence of pro-inflammatory mediators chiefly produced by
the microglia [44]. In this study we focused on evaluating the
ability of live B. burgdorferi to induce oligodendrocyte dam-
age in an in vitro system, using differentiated MO3.13
human oligodendrocytes and differentiated HOPC. We
addressed the hypothesis that inflammation plays a role in
mediating apoptosis of oligodendrocytes, as induced by B.
burgdorferi, using the anti-inflammatory drug dexametha-
sone. We included HOPC in our study to corroborate the
observations that we made with the MO3.13 cell line.
We established in vitro cultures of MO3.13 cells and
confirmed the presence of phenotypic markers that are
known to be expressed by this cell line, namely MBP
and GFAP [41].
Our first key observation was that B. burgdorferi is
able to induce the pro-inflammatory mediators CCL2,
IL-6, and IL-8 in oligodendrocytes. The levels of im-
mune mediators detected in the culture supernatants
increased concordantly with an increase in the spiroche-
tal MOI. HOPC similarly produced CCL2 and IL-8, a
finding that further validates the results obtained with
MO3.13 cells. These observations echo our previous
findings made with astrocytes and microglia, as these
glial cells also produced pro-inflammatory mediators in
response to live B. burgdorferi, and expand the scope of
our hypothesis of a role for glial cells in mediating in-
flammation in LNB [39,40,44-46]. Oligodendrocytes
could therefore contribute to the elevated levels of cyto-
kines and chemokines detected in the CSF of patients
with LNB [35-38].
Cytokines and chemokines play a central role in in-
flammation, demyelination, and neurodegeneration in
the CNS during inflammatory neurodegenerative dis-
eases such as multiple sclerosis (MS) [47]. Oligodendro-
cytes in brain tissue that is immediately adjacent to the
subarachnoid space, the region known as the sub-pial
space, are especially vulnerable to demyelination [48].
Since inflammatory lesions are commonly found in the
meninges in LNB, the myelitis that is seen in LNB may
be in part due to oligodendrocytes. These cells could be
damaged by the inflammatory process brought about by
the oligodendrocytes themselves, with participation of
other glial cells, in addition to inflammatory mediators
produced by the perivascular cellular infiltrates that are
often present in CNS infection. Oligodendrocytes are
known to express receptors for various cytokines and
chemokines [49].
CCL2 was induced at high levels in oligodendrocytes by
B. burgdorferi. This chemokine is of particular importance
in mediating inflammation in neurodegenerative diseases
[50]. CCL2 recruits monocytes and T cells from the blood
stream into the CNS during acute neuroinflammation, in
addition to recruiting microglia, the resident macrophages
of the brain [51]. It is an important mediator in many neu-
roinflammatory and neurodegenerative brain diseases char-
acterized by neuronal degeneration [52]. CCL2 has been
found to be up-regulated in actively demyelinating MS pla-
ques [53], and its expression is increased in experimental
autoimmune encephalomyelitis [54]. It is known to modu-
late microglial activation and proliferation, thus contribut-
ing to the inflammatory response mounted by the CNS
[55]. Importantly, CCL2 levels are elevated in the CSF of
patients with LNB [56], and we found high levels of CCL2
in the CSF of rhesus monkeys infected intrathecally with B.
burgdorferi [40]. CCL2 also has been documented to play a
role in mediating nerve damage and demyelination of axons
by causing influx of monocytes and T cells, in Wallerian de-
generation [57,58], and may thus contribute to the axonal
damage that affects patients with LNB of the PNS [10,11].
The cytokine IL-6, which was also elevated in the cul-
ture supernatants of oligodendrocytes that were exposed
to live B. burgdorferi, is known to be both helpful and
harmful in the CNS [31-34]. Dysregulated expression of
IL-6 has been documented in several neurological disor-
ders such as MS, acute transverse myelitis, Alzheimer’s
disease, schizophrenia, epileptic seizures, and Parkinson’s
disease [49]. In addition, IL-6 has been shown to be
involved in multiple physiological CNS processes such
as neuron homeostasis, astrogliogenesis, and neuronal
differentiation [59]. Elevated levels of IL-6 have also
been found in the CSF of LNB patients [35]. IL-6 is
known to promote oligodendrocyte and neuronal sur-
vival in the presence of glutamate-mediated excitotoxi-
city in hyppocampal slices [60]. IL-6 is also known to
support survival of oligodendrocytes in vitro [61].
The third pro-inflammatory mediator whose concen-
tration was significantly increased in culture superna-
tants of oligodendrocytes stimulated with live B.
burgdorferi is IL-8. This chemokine also has been
reported to be elevated in the CSF of LNB patients [62].
We had previously documented that B. burgdorferi
induces production of IL-8 in rhesus microglia, astro-
cytes and endothelial cells [39,40,44,46]. IL-8 released
into the CSF after brain injury is associated with blood-
brain barrier dysfunction and plays a central role in
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recruitment of neutrophils and T cells into the CNS
during bacterial meningitis [63,64].
Our second key observation was that live B. burgdorferi
induce a significantly elevated level of apoptosis, as
assessed by the TUNEL assay, in MO3.13 oligodendrocytes
compared to that seen in medium controls. The level of
apoptosis observed increased concordantly with an increase
in the B. burgdorferi MOI. We also observed elevated levels
of activated caspase-3, a phenomenon that is known to be
an early signaling event that results in apoptosis [65]. The
MO3.13 oligodendrocyte cell line used in these studies has
also been shown to undergo active caspase-3-mediated
apoptosis due to other stimuli such as ceramide [66,67],
and inflammatory cytokines [68]. Caspase-1, -2 and -3 are
known to be expressed in mature oligodendrocytes [69].
Caspase-mediated oligodendrocyte cell death (particularly
via activation of caspase-11 and caspase-3) has also been
documented in inflammatory demyelinating diseases such
as MS [70].
The interaction of B. burgdorferi with oligodendrocytes
resulted in elevated levels of inflammatory mediators
and concomitant apoptosis in oligodendrocytes, suggest-
ing that the phenomena of inflammation and apoptosis
might be causally related. To uncover the possible con-
nection between inflammation and apoptosis in this sys-
tem we treated both differentiated MO3.13 cells as well
as differentiated HOPC with the anti-inflammatory drug
dexamethasone. In both cases the effect was not only a
reduction in the amount of pro-inflammatory mediators,
as would be expected in the presence of dexamethasone,
but also a significant reduction in the fraction of cells
undergoing apoptosis. This outcome is a strong indica-
tion that inflammation plays a role in mediating oligo-
dendrocyte apoptosis.
Cytokines such as TNF, IL-1β, lymphotoxin (LT), and
TGF-β are known to cause cell death in oligodendrocytes
[71-74]. TNF and IL-1β were not detected in the culture
supernatants of oligodendrocytes that were incubated with
live B. burgdorferi for 48 h. TGF-β and LT were not among
the mediators that were detected by the human 14-plex
array that we used and may well have been present in the
culture supernatants. TNF, LT, [71] and TGF-β [72] were
shown to induce apoptosis in oligodendrocytes when added
exogenously, while IL-1β caused glutamate-mediated exci-
totoxic death of oligodendrocytes co-cultured with astro-
cytes and microglia [73], or when injected intra-cerebrally
in neonatal rats [74].
The potential of CCL2, IL-6, and/or IL-8 to induce
oligodendrocyte apoptosis has not been documented thus
far in the literature. In fact, IL-6 is known to promote the
survival of oligodendrocytes in culture [61]. IL-8 has been
shown to induce the expression of pro-inflammatory pro-
teases, matrix metalloproteinases MMP-2 and MMP-9,
cell-cycle protein cyclin D1, an early marker for G1/S
transition and pro-apoptotic protein Bim (Bcl-2-interact-
ing mediator of cell death), and cell death in cultured neu-
rons in 24 h [75]. CCL2 is implicated in mediating
oligodendrocyte/white matter damage indirectly by medi-
ating the influx of immune cells such as T cells and
macrophages, resulting in cytotoxic damage of the myelin
sheath of axons, followed by phagocytosis of myelin deb-
ris, culminating in demyelination and axonal damage [76].
A possible involvement of cytotoxic cells in the immune
response against B. burgdorferi has been suggested based
on in vitro studies [77], in addition to reports indicating
the presence of a cytolytic phenotype of IFN-γ producing
cells from patients with LNB [78]. It is likely that a simi-
lar mechanism may be mediating the demyelination and
axonal degeneration resulting in white matter lesions
seen in LNB [4,6,18-22].
The anti-inflammatory effect of dexamethasone, a
glucocorticoid used in the treatment of immune-
mediated inflammatory diseases is well documented
[42]. Dexamethasone has been shown to effectively re-
duce the levels of IL-6, IL-1β, and TNF released from
human monocytes stimulated with endotoxin to below
background levels [79]. Dexamethasone reduced the
levels of CCL2 in brain and retinal vascular endothelial
cells that were activated with pro-inflammatory cyto-
kines IL-1β, TNF, and IFN-γ [80]. The anti-inflammatory
potential of dexamethasone to reduce CCL2 and IL-8
also has been reported in cultured rheumatoid synovio-
cytes [81]. Here we show that dexamethasone can re-
duce the levels of CCL2, IL-6, and IL-8 as induced by B.
burgdorferi in differentiated human oligodendrocytes.
Clinical improvement was seen in a severe case of neu-
roborreliosis showing encephalomyelitis with polyneur-
opathy, when treated with the classically recommended
2 to 4 weeks of anti-microbial agents in combination
with steroids [82].
Dexamethasone has been shown to suppress CCL2 pro-
duction via mitogen-activated protein kinase phosphatase-1
(MAPK-P1)-dependent inhibition of Jun N-terminal kinase
and p38 MAPK in activated rat microglia [43]. MAPK cas-
cades are signal transduction pathways that play important
regulatory roles in the biosynthesis of pro-inflammatory
cytokines such as IL-6, IL-8, and CCL2 [83]. MAKP-P1, a
member of the Map Kinase Phosphatase family, is essential
for the dephosphorylation/deactivation of MAPK p38 and
JNK, thereby limiting pro-inflammatory cytokine biosyn-
thesis in innate immune cells exposed to microbial compo-
nents or infectious agents [84]. MAPK such as p38 and
JNK may be involved in the signaling mechanisms under-
lying both inflammation and apoptosis [83,85]. Earlier we
had documented the role of p38 MAPK, Erk1, and Erk 2 in
mediating the production of IL-6 and TNF, as well as apop-
tosis, in rhesus astrocytes as induced by lipoproteins of B.
burgdorferi [86]. MAPK signaling pathways may indeed be
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involved in regulating both inflammation and apoptosis as
induced by B. burgdorferi in human oligodendrocytes, as
well as in the modulatory effect of dexamethasone that we
observed.
Conclusions
In this study we have established that live B. burgdorferi
are capable of eliciting inflammatory mediators, particu-
larly IL-6, IL-8, and CCL2, in addition to inducing apop-
tosis in human oligodendrocyte cultures in vitro, by
activating caspase-3. Oligodendrocytes are the myelinating
cells of the CNS that myelinate neuronal axons, providing
saltatory conduction of action potentials and proper func-
tion of the CNS [87]. The role of oligodendrocyte death in
MS is well established [88]. Some of the earliest patho-
logical changes in inflammatory lesions seen in MS are
increases in oligodendrocyte apoptosis [89,90]. Based on
the observations of this study we propose that neurologic
injury in the CNS during an infection with the Lyme dis-
ease spirochete B. burgdorferi could be mediated in part by
the direct action of the spirochetes on oligodendrocytes or
via inflammation mediated by B. burgdorferi in oligoden-
drocytes. As oligodendrocytes are vital for the survival and
optimum function of neurons [91], oligodendrocyte dam-
age could contribute to neuronal dysfunction and death
and result in the impairment of CNS functions that are
seen in patients with LNB.
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